Clinical Trials Logo

Filter by:
NCT ID: NCT02316132 Withdrawn - Clinical trials for Irritable Bowel Syndrome

Confocal Laser Endomicroscopy, IBS and Stress

Start date: December 2014
Phase: N/A
Study type: Interventional

After standard endomicroscopy with fluorescein to investigate for dysplasia in Barrett's esophagus the endoscope will be forwarded into the 2nd part of the duodenum. Fluorescein is needed for CLE but is not part of the investigation. Initial CLE baseline images will be taken to assure intact mucosa and allow later detailed baseline counts of intraepithelial lymphocytes (IEL) and epithelial breaks in the duodenal mucosa. Thereafter, either 10 ml NaCl 0.9% or 100µg CRF topped up to 10ml with NaCL 0.9% (according to randomisation) will be injected intravenously. Endoscopist and assistant staff will be blinded to the randomisation. Subsequently, the gut surface will be examined for at least 5 min with endomicroscopy for any change in IEL, epithelial breaks/gaps with extrusion of fluorescein into the gut lumen and widening of intervillous space. Post procedure mucosal fluid will be aspirated for assessment of mast cell tryptase and eosin catatonic protein (ECP), and 8 duodenal biopsies will be taken for 1) electron microscopy to visualise mast cell degranulation and 2) paraffin embedding for subsequent staining for mast cell tryptase to identify mast cell activation and numbers. The procedure will take around 15 minutes in addition to the routine investigation performed prior to the study. A study outline is presented in figure 1. Samples taken are the same amount as done in the previous food associated study.

NCT ID: NCT02313207 Withdrawn - IBS Clinical Trials

Confocal Laser Endomicroscopy in IBS Patients

Start date: November 2014
Phase: N/A
Study type: Interventional

This study will assess dynamic effects of two major antigens on the duodenal mucosa by confocal laser endomicroscopy (CLE). Patients will be blinded to the antigens used (wheat, yeast). Following CLE it is planned to have a cross over exclusion diet with/without the antigens including a washout phase. Furthermore, patients will undergo a 2 week FODMAP diet to be able to compare results found of both diets and allow to understand whether our findings of food intolerance will be better and more precise than a common FODMAP diet. Post CLE food challenge patients biopsies will be taken for histology. They will then be randomized into two groups and blinded to the diet they undergo. They will be provided with a supply of custom-made bread they will have for 2 weeks (custom made by a bakery in Kiel). For one study arm bread will contain either wheat and yeast, for the other arm the bread will not contain these ingredients. The taste of the "normal" bread will be denaturised. Crossover will take place after a two-week washout phase.

NCT ID: NCT02302560 Withdrawn - Sleep Architecture Clinical Trials

Identification of the Sleep Architecture in Patients With Hip Surgery (TepSo)

Start date: February 2015
Phase:
Study type: Observational

The purpose of this prospective observational study is to investigate the changes in sleep architecture after a hip surgery and its potential association with postoperative delirium and postoperative cognitive dysfunctions respectively.

NCT ID: NCT02298712 Withdrawn - Clinical trials for Metabolism, Inborn Errors

Biomarker for Hurler Disease (BioHurler)

BioHurler
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Hurler disease from plasma. Testing for clinical robustness, specificity and long-term stability of the biomarker.

NCT ID: NCT02298699 Withdrawn - Developmental Delay Clinical Trials

Biomarker for Sly Disease (MPS VII) (BioSly)

BioSly
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Sly disease from blood (plasma)

NCT ID: NCT02298686 Withdrawn - Developmental Delay Clinical Trials

Biomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo)

BioSanfilippo
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the ear-ly and sensitive diagnosis of Sanfilippo Disease Type A-B-C-D from blood (plasma)

NCT ID: NCT02298673 Withdrawn - Clinical trials for Skeletal Abnormalities

Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)

BioML
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Mucolipidosis Disorder type I,II,III or IV from blood (plasma)

NCT ID: NCT02298647 Withdrawn - Seizures Clinical Trials

Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)

BioGM1/BioGM2
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the ear-ly and sensitive diagnosis of GM1/GM2 from blood

NCT ID: NCT02298634 Withdrawn - Splenomegaly Clinical Trials

Biomarker for Farber Disease (BioFarber)

BioFarber
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Farber disease from the blood

NCT ID: NCT02291276 Withdrawn - Clinical trials for Right Ventricular Function and Venous Return

Perioperative Assessment of Right Ventricular Function and Venous Return in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery (Gyn Right) - Pilot Study

Start date: November 2014
Phase: N/A
Study type: Observational

In this prospective, observational study the investigators assess the perioperative course of right ventricular function in combination with the venous return in patients undergoing major non-cardiac surgery. The study aims to investigate if patients undergoing major non-cardiac surgery develop an impairment of right ventricular function and/or venous return. Furthermore, the study evaluates if an impairment of right ventricular function and/or venous return is associated to left ventricular function, arterial side of the circulation and to postoperative clinical outcome.